世界の腎臓癌＆腎細胞癌（RCC）治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5819 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、腎臓癌＆腎細胞癌（RCC）治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アフィニトール（エベロリムス）、アバスチン（ベバシズマブ）、カボメティ（カボザンチニブ）、インリタ（アキシチニブ）、ネクサバール（ソラフェニブ）、プロロイキン（アルデスロイキン）、トリセル（テムシロリムス）、スーテント（スニチニブ）、ボトリエント（パゾパニブ））、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・腎臓癌＆腎細胞癌（RCC）治療薬の市場動向 ・企業の競争状況、市場シェア ・腎臓癌＆腎細胞癌（RCC）治療薬の種類別市場規模と予測2016-2027（アフィニトール（エベロリムス）、アバスチン（ベバシズマブ）、カボメティ（カボザンチニブ）、インリタ（アキシチニブ）、ネクサバール（ソラフェニブ）、プロロイキン（アルデスロイキン）、トリセル（テムシロリムス）、スーテント（スニチニブ）、ボトリエント（パゾパニブ）） ・腎臓癌＆腎細胞癌（RCC）治療薬の用途別市場規模と予測2016-2027（病院、クリニック、その他） ・腎臓癌＆腎細胞癌（RCC）治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・腎臓癌＆腎細胞癌（RCC）治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・腎臓癌＆腎細胞癌（RCC）治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・腎臓癌＆腎細胞癌（RCC）治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・腎臓癌＆腎細胞癌（RCC）治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Active Biotech Ab、Amgen、Bayer AG、Cipla Limited、Roche Holding AG、Glaxosmithkline Plc、Novartis Ag、Pfizer, Inc. ） ・結論

Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women.

Market Analysis and Insights: Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
The global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market.

Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Scope and Market Size
Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Afinitor (Everolimus)
Avastin (Bevacizumab)
Cabomety (Cabozantinib)
Inlyta (Axitinib)
Nexavar (Sorafenib)
Proleukin (Aldesleukin)
Torisel (Temsirolimus)
Sutent (Sunitinib)
Votrient (Pazopanib)

Segment by Application
Hospitals
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Active Biotech Ab
Amgen
Bayer AG
Cipla Limited
Roche Holding AG
Glaxosmithkline Plc
Novartis Ag
Pfizer, Inc. 

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Afinitor (Everolimus)
1.2.3 Avastin (Bevacizumab)
1.2.4 Cabomety (Cabozantinib)
1.2.5 Inlyta (Axitinib)
1.2.6 Nexavar (Sorafenib)
1.2.7 Proleukin (Aldesleukin)
1.2.8 Torisel (Temsirolimus)
1.2.9 Sutent (Sunitinib)
1.2.10 Votrient (Pazopanib)
1.3 Market by Application
1.3.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Perspective (2016-2027)
2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Growth Trends by Regions
2.2.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Industry Dynamic
2.3.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Trends
2.3.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers
2.3.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Challenges
2.3.4 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue
3.1.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue (2016-2021)
3.1.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue
3.4 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio
3.4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2020
3.5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players Head office and Area Served
3.6 Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service
3.7 Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Breakdown Data by Type
4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Type (2016-2021)
4.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Type (2022-2027)

5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Breakdown Data by Application
5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Application (2016-2021)
5.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2016-2027)
6.2 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type
6.2.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2021)
6.2.2 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2022-2027)
6.2.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2027)
6.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application
6.3.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2021)
6.3.2 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2022-2027)
6.3.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2027)
6.4 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country
6.4.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2016-2021)
6.4.2 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2016-2027)
7.2 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type
7.2.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2021)
7.2.2 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2022-2027)
7.2.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2027)
7.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application
7.3.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2021)
7.3.2 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2022-2027)
7.3.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2027)
7.4 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country
7.4.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2016-2021)
7.4.2 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2016-2027)
8.2 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type
8.2.1 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application
8.3.1 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region
8.4.1 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2016-2027)
9.2 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type
9.2.1 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2027)
9.3 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application
9.3.1 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2027)
9.4 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country
9.4.1 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2016-2027)
10.2 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type
10.2.1 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application
10.3.1 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country
10.4.1 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Active Biotech Ab
11.1.1 Active Biotech Ab Company Details
11.1.2 Active Biotech Ab Business Overview
11.1.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.1.4 Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
11.1.5 Active Biotech Ab Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.2.4 Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
11.2.5 Amgen Recent Development
11.3 Bayer AG
11.3.1 Bayer AG Company Details
11.3.2 Bayer AG Business Overview
11.3.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.3.4 Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
11.3.5 Bayer AG Recent Development
11.4 Cipla Limited
11.4.1 Cipla Limited Company Details
11.4.2 Cipla Limited Business Overview
11.4.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.4.4 Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
11.4.5 Cipla Limited Recent Development
11.5 Roche Holding AG
11.5.1 Roche Holding AG Company Details
11.5.2 Roche Holding AG Business Overview
11.5.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.5.4 Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
11.5.5 Roche Holding AG Recent Development
11.6 Glaxosmithkline Plc
11.6.1 Glaxosmithkline Plc Company Details
11.6.2 Glaxosmithkline Plc Business Overview
11.6.3 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.6.4 Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
11.6.5 Glaxosmithkline Plc Recent Development
11.7 Novartis Ag
11.7.1 Novartis Ag Company Details
11.7.2 Novartis Ag Business Overview
11.7.3 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.7.4 Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
11.7.5 Novartis Ag Recent Development
11.8 Pfizer, Inc. 
11.8.1 Pfizer, Inc.  Company Details
11.8.2 Pfizer, Inc.  Business Overview
11.8.3 Pfizer, Inc.  Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.8.4 Pfizer, Inc.  Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
11.8.5 Pfizer, Inc.  Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Afinitor (Everolimus)
Table 3. Key Players of Avastin (Bevacizumab)
Table 4. Key Players of Cabomety (Cabozantinib)
Table 5. Key Players of Inlyta (Axitinib)
Table 6. Key Players of Nexavar (Sorafenib)
Table 7. Key Players of Proleukin (Aldesleukin)
Table 8. Key Players of Torisel (Temsirolimus)
Table 9. Key Players of Sutent (Sunitinib)
Table 10. Key Players of Votrient (Pazopanib)
Table 11. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 12. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 13. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 14. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2016-2021)
Table 15. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 16. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2022-2027)
Table 17. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Trends
Table 18. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers
Table 19. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Challenges
Table 20. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints
Table 21. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 22. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players (2016-2021)
Table 23. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2020)
Table 24. Ranking of Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies by Revenue (US$ Million) in 2020
Table 25. Global 5 Largest Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service
Table 28. Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 31. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2016-2021)
Table 32. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 33. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 34. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 35. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Application (2016-2021)
Table 36. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 37. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 38. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 39. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 40. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 41. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 42. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 43. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 44. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 45. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 46. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 47. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 48. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 49. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 51. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 52. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 53. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 54. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 55. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 56. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 57. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 58. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 59. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 60. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 61. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 63. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 64. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 65. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 66. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 67. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 68. Active Biotech Ab Company Details
Table 69. Active Biotech Ab Business Overview
Table 70. Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 71. Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021) & (US$ Million)
Table 72. Active Biotech Ab Recent Development
Table 73. Amgen Company Details
Table 74. Amgen Business Overview
Table 75. Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 76. Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021) & (US$ Million)
Table 77. Amgen Recent Development
Table 78. Bayer AG Company Details
Table 79. Bayer AG Business Overview
Table 80. Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 81. Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021) & (US$ Million)
Table 82. Bayer AG Recent Development
Table 83. Cipla Limited Company Details
Table 84. Cipla Limited Business Overview
Table 85. Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 86. Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021) & (US$ Million)
Table 87. Cipla Limited Recent Development
Table 88. Roche Holding AG Company Details
Table 89. Roche Holding AG Business Overview
Table 90. Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 91. Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021) & (US$ Million)
Table 92. Roche Holding AG Recent Development
Table 93. Glaxosmithkline Plc Company Details
Table 94. Glaxosmithkline Plc Business Overview
Table 95. Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 96. Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021) & (US$ Million)
Table 97. Glaxosmithkline Plc Recent Development
Table 98. Novartis Ag Company Details
Table 99. Novartis Ag Business Overview
Table 100. Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 101. Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021) & (US$ Million)
Table 102. Novartis Ag Recent Development
Table 103. Pfizer, Inc.  Company Details
Table 104. Pfizer, Inc.  Business Overview
Table 105. Pfizer, Inc.  Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021) & (US$ Million)
Table 106. Pfizer, Inc.  Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type: 2020 VS 2027
Figure 2. Afinitor (Everolimus) Features
Figure 3. Avastin (Bevacizumab) Features
Figure 4. Cabomety (Cabozantinib) Features
Figure 5. Inlyta (Axitinib) Features
Figure 6. Nexavar (Sorafenib) Features
Figure 7. Proleukin (Aldesleukin) Features
Figure 8. Torisel (Temsirolimus) Features
Figure 9. Sutent (Sunitinib) Features
Figure 10. Votrient (Pazopanib) Features
Figure 11. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application: 2020 VS 2027
Figure 12. Hospitals Case Studies
Figure 13. Clinic Case Studies
Figure 14. Others Case Studies
Figure 15. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Report Years Considered
Figure 16. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 17. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 18. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions: 2020 VS 2027
Figure 19. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2022-2027)
Figure 20. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players in 2020
Figure 21. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2020
Figure 22. The Top 10 and 5 Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2020
Figure 23. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2016-2021)
Figure 24. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2022-2027)
Figure 25. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2016-2027)
Figure 27. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2016-2027)
Figure 28. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2016-2027)
Figure 29. United States Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Canada Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2016-2027)
Figure 33. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2016-2027)
Figure 34. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2016-2027)
Figure 35. Germany Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. France Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. U.K. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Italy Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Russia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Nordic Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2016-2027)
Figure 43. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2016-2027)
Figure 44. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region (2016-2027)
Figure 45. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Australia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2016-2027)
Figure 53. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2016-2027)
Figure 54. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2016-2027)
Figure 55. Mexico Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Brazil Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2016-2027)
Figure 59. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2016-2027)
Figure 60. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2016-2027)
Figure 61. Turkey Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Saudi Arabia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. UAE Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 64. Active Biotech Ab Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
Figure 65. Amgen Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
Figure 66. Bayer AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
Figure 67. Cipla Limited Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
Figure 68. Roche Holding AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
Figure 69. Glaxosmithkline Plc Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
Figure 70. Novartis Ag Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
Figure 71. Pfizer, Inc.  Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2016-2021)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed

---